Advanced search

Vol 61, No 3 (2023)
Original paper
Published online: 2023-10-03

open access

View PDF Download PDF file
Page views 617
Article views/downloads 339
Get Citation

Connect on Social Media

Connect on Social Media

Expression of CD105 but not of E-cadherin is associated with malignancy recurrence and disease-free interval in laryngeal cancer in men

Elvir Zvrko12, Ljiljana Vuckovic23
DOI: 10.5603/fhc.97035
Pubmed: 37787034
Folia Histochem Cytobiol 2023;61(3):183-192.

Abstract

Introduction. In this study we analyzed CD105 (endoglin) and E-cadherin expression in laryngeal squamous cell carcinoma (LSCC) to evaluate their clinicopathologic significance.

Material and methods. Expression of CD105 and E-cadherin was examined immunohistochemically using paraffin-embedded archival tissues of 72 (35 glottic and 37 supraglottic) previously untreated LSCC male patients. The mean value of the positively-stained microvessels for CD105 counted in four hot spots for each case was used as the final intratumoralmicrovessel density (MVD). A staining score of E-cadherin was calculated based on the percentage of cells stained (0–100%).

Results. MVD was significantly higher in patients with advanced TNM stage (P = 0.004) and younger than 65 (P = 0.008). Nodal metastases were more frequent in the cases with low E-cadherin expression (P = 0.000). Tumor recurrence was associated with advanced TNM stage (P = 0.035) and high MVD (P = 0.002). A high MVD was an independent predictor of malignancy recurrence (P = 0.021). The log-rank test showed a significant difference in the disease-free interval in patients stratified according to the MVD value (P = 0.016). Spearman’s rank correlation test did not show a significant correlation between E-cadherin and CD105 expression.

Conclusions. CD105-assessed MVD and expression of E-cadherin are promising prognostic factors for the outcome of patients with LSCC. Increased expression of CD105 could help predict patients with an increased risk of developing loco-regional recurrence after surgical treatment. Decreased E-cadherin expression is a potential predictor of lymph node metastases.

Keywords: laryngeal carcinomaCD105angiogenesisE-cadherinMVDimmunohistochemistry

Article available in PDF format

View PDF Download PDF file

References

  1. Nocini R, Molteni G, Mattiuzzi C, et al. Updates on larynx cancer epidemiology. Chin J Cancer Res. 2020; 32(1): 18–25.
    CrossRefPubMed
  2. Bradford CR, Ferlito A, Devaney KO, et al. Prognostic factors in laryngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2020; 5(1): 74–81.
    CrossRefPubMed
  3. Prognostic factor definition. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/prognostic-factor (6.01.2023).
  4. Johansen LV, Grau C, Overgaard J. Laryngeal carcinoma — multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. Acta Oncol. 2003; 42(7): 771–778.
    CrossRefPubMed
  5. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007; 133(12): 1270–1276.
    CrossRefPubMed
  6. Bøje CR. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma — a systematic review. Radiother Oncol. 2014; 110(1): 81–90.
    CrossRefPubMed
  7. Li ZQ, Zou L, Liu TR, et al. Prognostic value of body mass index before treatment for laryngeal squamous cell carcinoma. Cancer Biol Med. 2015; 12(4): 394–400.
    CrossRefPubMed
  8. Bonner J, Giralt J, Harari P, et al. Cetuximab and radiotherapy in laryngeal preservation for cancers of the larynx and hypopharynx: a secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2016; 142(9): 842–849.
    CrossRefPubMed
  9. Atef A, El-Rashidy MA, Elzayat S, et al. The prognostic value of sex hormone receptors expression in laryngeal carcinoma. Tissue Cell. 2019; 57: 84–89.
    CrossRefPubMed
  10. Ahmadi N, Ahmadi N, Chan MV, et al. Laryngeal squamous cell carcinoma survival in the context of human papillomavirus: a systematic review and meta-analysis. Cureus. 2018; 10(2): e2234.
    CrossRefPubMed
  11. Coca-Pelaz A, Rodrigo JP, Suárez C, et al. The risk of second primary tumors in head and neck cancer: a systematic review. Head Neck. 2020; 42(3): 456–466.
    CrossRefPubMed
  12. Franz L, Nicolè L, Frigo AC, et al. Epithelial-to-mesenchymal transition and neoangiogenesis in laryngeal squamous cell carcinoma. Cancers (Basel). 2021; 13(13).
    CrossRefPubMed
  13. Litwiniuk-Kosmala M, Makuszewska M, Czesak M. Endoglin in head and neck neoplasms. Front Med (Lausanne). 2023; 10: 1115212.
    CrossRefPubMed
  14. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004; 57(6): 591–597.
    CrossRefPubMed
  15. Nagatsuka H, Hibi K, Gunduz M, et al. Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinomas. J Oral Pathol Med. 2005; 34(2): 70–76.
    CrossRefPubMed
  16. Li SL, Gao DL, Zhao ZH, et al. Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma. World J Gastroenterol. 2007; 13(45): 6076–6081.
    CrossRefPubMed
  17. Sánchez-Elsner T, Botella LM, Velasco B, et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. 2002; 277(46): 43799–43808.
    CrossRefPubMed
  18. Miyata Y, Sagara Y, Watanabe Si, et al. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34. Virchows Arch. 2013; 463(5): 673–679.
    CrossRefPubMed
  19. Marioni G, Giacomelli L, D’Alessandro E, et al. Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. Anticancer Res. 2008; 28(1B): 551–557.
    PubMed
  20. Zvrko E, Mikic A, Vuckovic L. CD105 expression as a measure of microvessel density in supraglottic laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2009; 266(12): 1971–1976.
    CrossRefPubMed
  21. Zvrko E, Mikic A, Vuckovic L, et al. Prognostic relevance of CD105-assessed microvessel density in laryngeal carcinoma. Otolaryngol Head Neck Surg. 2009; 141(4): 478–483.
    CrossRefPubMed
  22. Lovato A, Marioni G, Manzato E, et al. Elderly patients at higher risk of laryngeal carcinoma recurrence could be identified by a panel of two biomarkers (nm23-H1 and CD105) and pN+ status. Eur Arch Otorhinolaryngol. 2015; 272(11): 3417–3424.
    CrossRefPubMed
  23. Marioni G, Franz L, Ottaviano G, et al. Prognostic significance of CD105- and CD31-assessed microvessel density in paired biopsies and surgical samples of laryngeal carcinoma. Cancers (Basel). 2020; 12(8).
    CrossRefPubMed
  24. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6): 1420–1428.
    CrossRefPubMed
  25. Loh CY, Chai JYi, Tang TF, et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells. 2019; 8(10).
    CrossRefPubMed
  26. Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, et al. Role of cadherins in cancer — a review. Int J Mol Sci. 2020; 21(20).
    CrossRefPubMed
  27. Piprek RP, Kloc M, Mizia P, et al. The central role of cadherins in gonad development, reproduction, and fertility. Int J Mol Sci. 2020; 21(21).
    CrossRefPubMed
  28. Punovuori K, Malaguti M, Lowell S. Cadherins in early neural development. Cell Mol Life Sci. 2021; 78(9): 4435–4450.
    CrossRefPubMed
  29. Marioni G, Nicolè L, Cappellesso R, et al. β-Arrestin-1 expression and epithelial-to-mesenchymal transition in laryngeal carcinoma. Int J Biol Markers. 2019; 34(1): 33–40.
    CrossRefPubMed
  30. Zvrko E, Mikić A, Jancić S. Relationship of E-cadherin with cervical lymph node metastasis in laryngeal cancer. Coll Antropol. 2012; 36 Suppl 2: 119–124.
    PubMed
  31. Zhu GJ, Song PP, Zhou H, et al. Role of epithelial-mesenchymal transition markers E-cadherin, N-cadherin, β-catenin and ZEB2 in laryngeal squamous cell carcinoma. Oncol Lett. 2018; 15(3): 3472–3481.
    CrossRefPubMed
  32. Zhang M, Li H, Han Y, et al. Clinicopathological significance of SOX4 and epithelial-mesenchymal transition markers in patients with laryngeal squamous cell carcinoma. Medicine (Baltimore). 2021; 100(12): e25028–1175.
    CrossRefPubMed
  33. Paksoy M, Hardal U, Caglar C. Expression of cathepsin D and E-cadherin in primary laryngeal cancers correlation with neck lymph node involvement. J Cancer Res Clin Oncol. 2011; 137(9): 1371–1377.
    CrossRefPubMed
  34. Yüce İ, Çağlı S, Canöz Ö, et al. Predictive value of E-cadherin and Ep-CAM in cervical lymph node metastasis of supraglottic larynx carcinoma. Am J Otolaryngol. 2015; 36(6): 736–740.
    CrossRefPubMed
  35. Barutçu O, Kara M, Muratlı A, et al. Clinical significance of Ki-67, c-erbB-2 and E-cadherin expressions in open partial laryngectomy patients. Kulak Burun Bogaz Ihtis Derg. 2016; 26(5): 283–292.
    CrossRefPubMed
  36. Kejner AE, Li H, Li EY, et al. Treatment modality and outcomes in larynx cancer patients: A sex-based evaluation. Head Neck. 2019; 41(11): 3764–3774.
    CrossRefPubMed
  37. Saini AT, Genden EM, Megwalu UC. Sociodemographic disparities in choice of therapy and survival in advanced laryngeal cancer. Am J Otolaryngol. 2016; 37(2): 65–69.
    CrossRefPubMed
  38. Fakhry C, Westra WH, Wang SJ, et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer. 2017; 123(9): 1566–1575.
    CrossRefPubMed
  39. Monden N, Asakage T, Kiyota N, et al. Head and Neck Cancer Study Group (HNCSG). A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition). Jpn J Clin Oncol. 2019; 49(7): 589–595.
    CrossRefPubMed
  40. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1): 1–8.
    CrossRefPubMed
  41. Saad RS, Liu YL, Nathan G, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004; 17(2): 197–203.
    CrossRefPubMed
  42. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999; 59(4): 856–861.
    PubMed
  43. Yagasaki H, Kawata N, Takimoto Y, et al. Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol. 2003; 10(4): 220–227.
    CrossRefPubMed
  44. Martone T, Rosso P, Albera R, et al. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol. 2005; 41(2): 147–155.
    CrossRefPubMed
  45. Kyzas PA, Agnantis NJ, Stefanou D. Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch. 2006; 448(6): 768–775.
    CrossRefPubMed
  46. Gu X, Xu Y, Wu He, et al. [Relationship between CD105 and angiogenesis and biological behaviors in squamous carcinoma of larynx]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006; 20(3): 125–128.
    PubMed
  47. Chen HC, Chu RY, Hsu PN, et al. Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. Cancer Lett. 2003; 201(1): 97–106.
    CrossRefPubMed
  48. Köksal IT, Ozcan F, Kiliçaslan I, et al. Expression of E-cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features. Pathology. 2002; 34(3): 233–238.
    CrossRefPubMed
  49. Kanazawa T, Watanabe T, Kazama S, et al. Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer. 2002; 102(3): 225–229.
    CrossRefPubMed
  50. Sarrió D, Pérez-Mies B, Hardisson D, et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene. 2004; 23(19): 3272–3283.
    CrossRefPubMed
  51. Franchi A, Gallo O, Boddi V, et al. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination. Clin Cancer Res. 1996; 2(10): 1801–1808.
    PubMed
  52. Rodrigo JP, Domínguez F, Alvarez C, et al. Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer. 2002; 38(8): 1059–1064.
    CrossRefPubMed
  53. Akdeniz O, Akduman D, Haksever M, et al. Relationships between clinical behavior of laryngeal squamous cell carcinomas and expression of VEGF, MMP-9 and E-cadherin. Asian Pac J Cancer Prev. 2013; 14(9): 5301–5310.
    CrossRefPubMed
  54. Ahmed RA, Shawky AEA, Hamed RH. Prognostic significance of cyclin D1 and E-cadherin expression in laryngeal squamous cell carcinoma. Pathol Oncol Res. 2014; 20(3): 625–633.
    CrossRefPubMed
  55. Andrews NA, Jones AS, Helliwell TR, et al. Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br J Cancer. 1997; 75(10): 1474–1480.
    CrossRefPubMed
  56. Takes RP, Baatenburg de Jong RJ, Schuuring E, et al. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1997; 123(4): 412–419.
    CrossRefPubMed
  57. Cappellesso R, Marioni G, Crescenzi M, et al. The prognostic role of the epithelial-mesenchymal transition markers E-cadherin and Slug in laryngeal squamous cell carcinoma. Histopathology. 2015; 67(4): 491–500.
    CrossRefPubMed
  58. Li Q, Zhang B, Peng P. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007; 21(24): 1114–1117.
    PubMed
  59. Marioni G, Ottaviano G, Giacomelli L, et al. CD105-assessed micro-vessel density is associated with malignancy recurrence in laryngeal squamous cell carcinoma. Eur J Surg Oncol. 2006; 32(10): 1149–1153.
    CrossRefPubMed
  60. Gordon MS, Robert F, Matei D, et al. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014; 20(23): 5918–5926.
    CrossRefPubMed
  61. Dorff TB, Longmate JA, Pal SK, et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017; 123(23): 4566–4573.
    CrossRefPubMed
  62. Galanis E, Anderson SK, Twohy E, et al. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neurooncol Adv. 2022; 4(1): vdac041.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note